QURE uniQure Corp: Projected Price to Earnings

Graphic logo of uniQure Pharma (QURE)

Dutch biotech firm uniQure N.V. (QURE), which holds patents and partnerships with industry giants, shows a notable peak on the chart. The forward P/E valuation trend for uniQure N.V. (QURE) indicates that the current metric is 0.00. Business resilience is supported by royalties and a diversified drug pipeline. Stability is ensured by an optimized staff of leading vectorology experts, which has preserved key R&D potential.

Future Price to Earnings Multiple: uniqure.com (QURE) for 07/04/2022 - 11/17/2026

Financial and market metric breakdowns for uniqure.com (QURE)

- stock value and consensus price forecast:
- company stock capitalization data:
Summary company analytics:uniQure Pharma QURE
Product sample of uniQure N.V.

Investors utilize forward multiples to verify the fundamental stability of an issuer. This metric correlates current market capitalization with expected net income, reflecting market expectations for business efficiency. By analyzing the forward P/E history of a company, one can assess the fairness of the current share price. For uniQure N.V. (QURE), as a recognized leader in gene therapy, this metric serves as an indicator of market confidence in the future commercialization of scientific developments. A decrease in the ratio confirms the transition from the research stage to actual profitability.

Main competitors

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|MAZE: Forward P/E Multiple|Sionna Therapeutics, Inc. (SION) - Forward P/E Multiple|Future Price to Earnings Prime Medicine, Inc.|TSHA (Taysha) - Market Cap to Future Earnings Ratio|Forward P/E Multiple MGTX|Market Cap to Projected Earnings regenxbio.com|Forward P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Future Earnings Ratio|PACB - Future Price to Earnings|Benitec (BNTC) - Projected Price to Earnings|DSGN: Forward P/E Multiple|RCKT: Market Cap to Future Earnings Ratio|FDMT (4D Molecular Therapeutics, Inc.) - Forward P/E Multiple|lexeotx.com (LXEO) - Market Cap to Projected Earnings|Forward P/E Multiple KRRO|Projected Price to Earnings Editas Medicine, Inc. EDIT|Future Price to Earnings silence-therapeutics.com SLN|PRQR: Price to Future Earnings Ratio|CDXS - Future Price to Earnings|Market Cap to Projected Earnings Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple